tbuckley/cabot-search huggingface dataset:
TIMP-2 on the cell membrane promotes leukemic cells SHI-1 proliferation and invasion in immunodeficiency mice
Authors: Zhen-Jiang Li, Zi-Xing Chen, Jian-Nong Cen, Jun He, Qiao-Cheng Qiu
Journal: Cancer Research (2006)

257   Acute leukemia, especially for the acute monocytic leukemia, were frequently accompanied by extramedullary infiltrations. MMPs and TIMPs are thought to be involved in the infiltration and invasion in solid tumors. Our laboratory had established a SCI- nu/nu  mice model of extramedullary infilatration by using a human monocytic leukemic cell line SHI-1. In the present study we aimed to investigate the functions of TIMP-2 on the growth and infiltration of SHI-1 cells in SCI- nu/nu  mice. Retroviral vector MSCV carrying human TIMP-2 cDNA was constructed and transfected into SHI-1 cells. The expression of TIMP-2 was detected by real-time PCR, western-blotting and FCM. SHI-1 cells proliferation was examined by MTT and the invasive capability was detected by trans-matrigel invasion assay using transwell chambers. The trasfected SHI-1 cells were IV injected into  nu/nu  mice pretreated by splenectomy, cytoxan intraperitoneal injection, and sublethal irradiation (referred to as SCI- nu/nu  mice). Mice were sacrified within 30 days after IV challenged with SHI-1 cells. All tissues from variety of organs were properly sectioned and stained. CNSL were graded based on the degree of leukemia cell infiltration into the brain. A 2.975 times higher of TIMP-2 mRNA in SHI-1/TIMP-2 cells than in SHI-1/MSCV cells was found. TIMP-2 expressed on the SHI-1/TIMP-2 cells (99.3%±0.1%) were significantly higher than that on SHI-1/MSCV cells (85.9%±2.6%), with an 2.06 times increase in fluorescent intensity. In company with a faster proliferation rate, SHI-1/TIMP-2 cells demonstrated significantly stronger ability of trans-matrigel invasion. The median survival time of SCI- nu/nu  mice with SHI-1/TIMP-2 were 33.7 days (30-40days), significantly shorter than 40 days (36-44days) in those with SHI-1/MSCV. The SCI- nu/nu  mice inoculated with SHI-1/TIMP-2 cells demonstrated more remarkable features of leukemic infiltration than those inoculated with SHI-1/MSCV cells, evidenced by both gross anatomical and histopathological observations. More serious central nervous system infiltration (higher percentage in higher degrees ) were also found in the brain of the SCI- nu/nu  mice injected with SHI-1/TIMP-2 cells. By contrary to the notion that TIMP-2 inhibits the infiltration in solid tumor, our results that SHI-1/TIMP-2 cells overexpressing TIMP-2 enhance proliferation and infiltration of leukemia cells in SCI- nu/nu  mice, may be attributed to the activation of proMMP by TIMP-2 through the formation of more MT1-MMP-TIMP-2-proMMP-2 complexes on the cell membrane, and resulting in the higher invasion of SHI-1/TIMP-2 cells in the SCI- nu/nu  mice. These results suggest that higher expression TIMP-2 in leukemia may promote instead of inhibit the leukemic extramedullary infiltration.
The Proteome of Primary Prostate Cancer
Authors: Diego Iglesias-Gato, Pernilla Wikström, Stefka Tyanova, Charlotte Lavallee, Elin Thysell, Jessica Carlsson, Christina Hägglöf, Jürgen Cox, Ove Andrén, Pär Stattin, Lars Egevad, Anders Widmark, Anders Bjartell, Colin C. Collins, Anders Bergh, Tamar Geiger, Matthias Mann, Amilcar Flores-Morales
Journal: European Urology (2015)
Behavioral Programs for Type 1 Diabetes Mellitus
Authors: Jennifer Pillay, Marni J. Armstrong, Sonia Butalia, Lois E. Donovan, Ronald J. Sigal, Pritam Chordiya, Sanjaya Dhakal, Ben Vandermeer, Lisa Hartling, Megan Nuspl, Robin Featherstone, Donna M. Dryden
Journal: Annals of Internal Medicine (2015)

Whether behavioral approaches for self-management programs benefit individuals with type 1 diabetes mellitus is unclear.To determine the effects of behavioral programs for patients with type 1 diabetes on behavioral, clinical, and health outcomes and to investigate factors that might moderate effect.6 electronic databases (1993 to June 2015), trial registries and conference proceedings (2011 to 2014), and reference lists.36 prospective, controlled studies involving participants of any age group that compared behavioral programs with usual care, active controls, or other programs.One reviewer extracted and another verified data. Two reviewers assessed quality and strength of evidence (SOE).Moderate SOE showed reduction in glycated hemoglobin (HbA1c) at 6 months after the intervention compared with usual care (mean difference, -0.29 [95% CI, -0.45 to -0.13] percentage points) and compared with active controls (-0.44 [CI, -0.69 to -0.19] percentage points). At the end of the intervention and 12-month follow-up or longer, there were no statistically significant differences in HbA1c (low SOE) for comparisons with usual care or active control. Compared with usual care, generic quality of life at program completion did not differ (moderate SOE). Other outcomes had low or insufficient SOE. Adults appeared to benefit more for glycemic control at program completion (-0.28 [CI, -0.57 to 0.01] percentage points) than did youth (-0.12 [CI, -0.43 to 0.19] percentage points). Program intensity appeared not to influence effectiveness; some individual delivery appears beneficial.All studies had medium or high risk of bias. There was scarce evidence for many outcomes.Behavioral programs for type 1 diabetes offer some benefit for glycemic control, at least at short-term follow-up, but improvement for other outcomes has not been shown. (PROSPERO registration number: CRD42014010515).Agency for Healthcare Research and Quality. (PROSPERD registration number: CRD42014010515).
CTS™ immune cell SR for serum free culture and expansion of human T cells
Authors: Grethe Okern, Angel Varela-Rohena, Sandra Kuligowski, Brian Newsom, Tanja Aarvak
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts The manufacture of a majority of clinical T cell products for immunotherapy applications requires in vitro T cell culture and expansion. Commercialization of T cell manufacturing processes requires reagents that meet regulatory guidelines and ultimately help reduce manufacturing
Dosimetry in Pleural Photodynamic Therapy
Authors: Timothy C. Zhu
Journal: Journal of the National Comprehensive Cancer Network (2012)

Photodynamic therapy (PDT) centers on the photochemical interaction of 3 principal components: light, photosensitizer, and oxygen. Over the past 25 years, much has been learned about the basic biophysical mechanisms of PDT, and in the future, a clearer understanding of the physics of PDT will make it possible to translate this science into improved clinical treatments. This article explores the role of explicit dosimetry in PDT and the need for individualized determination of dosimetric parameters based on the heterogeneity of optical properties and photosensitizer drug concentration. In addition, the use of a navigation system to help deliver uniform light for pleural PDT is briefly discussed.
Bizarre delusions and DSM-III-R schizophrenia
Authors: D Goldman, D A Hien, G L Haas, J A Sweeney, A J Frances
Journal: American Journal of Psychiatry (1992)

Bizarre delusions are assigned greater weight relative to other delusions in the DSM-III-R diagnosis of schizophrenia. The decision to emphasize bizarre delusions was based largely on historical tradition rather than empirical evidence. This study examined 1) the extent to which a history of bizarre delusions contributes to the diagnosis of schizophrenia and 2) whether schizophrenic patients with bizarre delusions constitute a clinically distinguishable subgroup.Two hundred fourteen consecutively admitted psychotic inpatients were assessed for bizarre delusions according to the DSM-III-R criteria. Clinical and demographic correlates of bizarre delusions were examined in subsets of patients diagnosed as schizophrenic according to DSM-III-R who also received CT scans and neuropsychological testing.With the base prevalence rate for schizophrenia of 0.71, bizarre delusions had a sensitivity of 0.79, a specificity of 0.56, and a positive predictive power of 0.82 for the diagnosis of schizophrenia (N = 152) relative to other psychotic disorders (N = 62). Clinical, neurobehavioral, CT scan, and premorbid adjustment data on the schizophrenic patients indicated that beyond manifesting more severe positive symptoms, patients with bizarre delusions did not otherwise constitute a clinically distinguishable subgroup.The data suggest that criterion A for the diagnosis of schizophrenia in DSM-IV could be improved by removing the special emphasis that was placed on bizarre delusions in DSM-III-R.
The stigma of mental health in athletes: are mental toughness and mental health seen as contradictory in elite sport?
Authors: N James Bauman
Journal: British Journal of Sports Medicine (2015)

Mental illness and the stigma attached to those suffering from its affects have been part of human existence throughout history.1 Despite efforts to bring more awareness to the causation and effective treatment of mental health issues, this stigma persists both socially and in the athletic culture. Long established beliefs have proven to be as challenging to change as many of the other discriminatory practices receiving media attention, political dialogue and legal debate (eg, race, gender, religion, sexual orientation, gay marriage, immigration, legalisation of recreational drugs). Although these other issues have their own set of challenges that inhibit healthy social change, a thread of historical stereotyping is common to all of them, including mental health.

The US Department of Health and Services (USDHS) reported in 2012 that 1 in 5 adults (20%) experience a mental health issue each year.2 USDHS also reported that rate increased to 30% in the age group …
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
Authors: Shruti Agrawal, Yan Feng, Amit Roy, Georgia Kollia, Brian Lestini
Journal: Journal for ImmunoTherapy of Cancer (2016)

Immuno-oncology (I-O) therapies target the host immune system, providing the potential to choose a uniform dose and schedule across tumor types. However, dose selection for I-O agents usually occurs early in clinical development and is typically based on tumor response, which may not fully represent the potential for improved overall survival. Here, we describe an integrated approach which incorporates clinical safety and efficacy data with data obtained from analyses of dose-/exposure-response (D-R/E-R) relationships, used to select a monotherapy dose for nivolumab, a programmed death-1 inhibitor, in clinical studies of different tumor types.Dose was selected based on anti-tumor activity and safety data from a large phase 1b, open-label, dose-escalation study of nivolumab at doses ranging from 0.1 to 10 mg/kg administered every 2 weeks (Q2W) in 306 patients with advanced malignancies, and quantitative analyses were performed to characterize D-R/E-R relationships for pharmacodynamic, safety, and efficacy endpoints.A maximum tolerated dose for nivolumab was not identified, and the safety profile was similar across tumor types and dose levels (0.1-10 mg/kg). Objective response rates (ORRs) were similar across doses in melanoma and renal cell carcinoma (RCC), while higher ORRs were observed in non-small cell lung cancer (NSCLC) at 3 mg/kg and 10 mg/kg versus 1 mg/kg. Peripheral receptor occupancy was saturated at doses ≥ 0.3 mg/kg. In D-R/E-R analyses, a positive dose-dependent objective response trend was observed for each tumor type, but appeared to plateau at nivolumab doses of ≥ 1 mg/kg for melanoma and RCC, and at ≥ 3 mg/kg for NSCLC. Although there was no apparent relationship between tumor shrinkage rate and exposure, tumor progression rate appeared to decrease with increasing exposure up to a dose of 3 mg/kg Q2W for NSCLC.Nivolumab monotherapy at 3 mg/kg Q2W provides unified dosing across tumor types. This dose and schedule has been validated in several phase II/III studies in which overall survival was an endpoint. Integrating D-R/E-R relationships with efficacy data and a safety profile that is unique to I-O therapy is a rational approach for dose selection of these agents.
Epidémie de trichinellose en région midi-Pyrénées, France, janvier - mars 1998
Authors: S Haeghebaert, M Servat, C Duchen, J C Minet, A EAgrech, I Thièse, C Leclerc, V Vaillant, C Hemery, E Maillot, C Soulé, E Pozio, P Massip, J. F. Magnaval, J C Desenclos
Journal: Eurosurveillance (1998)

Le 2 mars 1998, le Reseau National de Sante Publique (RNSP) etait informe par les autorites sanitaires du departement du Tarn et Garonne de la survenue de deux foyers de trichinellose, en fevrier dans ce departement. 
Une enquete epidemiologique a ete mise en œuvre le 3 mars afin de mesurer l’importance de l’epidemie, d’identifier la source et le vehicule alimentaire et de proposer des mesures de controle.
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion
Authors: Virginie Chesnais, Aline Renneville, Andrea Toma, Jérôme Lambert, Marie Passet, Florent Dumont, Sylvie Chevret, Julie Lejeune, Anna Raimbault, Aspasia Stamatoullas, Christian Rose, Odile Beyne-Rauzy, Jacques Delaunay, Eric Solary, Pierre Fenaux, François Dreyfus, Claude Preudhomme, Olivier Kosmider, Michaela Fontenay
Journal: Blood (2015)
Equity in Cancer Care: Pathways, Protocols, and Guidelines
Authors: Jessica K. DeMartino, Jonathan K. Larsen
Journal: Journal of the National Comprehensive Cancer Network (2012)

The quality of patient care varies based on numerous factors, such as health care setting, geographic location, access to medications, insurance coverage, and treatment protocols. Recently, the issue of whether use of clinical pathways can reduce costs and inappropriate variability in care has been the subject of much debate. As clinical treatment guidelines and pathways are increasingly deployed in oncology practice, they have a growing impact on the quality of treatment and how it is delivered. To fulfill the current need to discuss the use of pathways and clinical treatment guidelines in oncology and to address how patient care is impacted by their use, the National Comprehensive Cancer Network convened the NCCN Oncology Policy Summit: Equity in Cancer Care–Pathways, Protocols, and Guidelines. The summit was a forum to discuss the use and implementation of pathways, including how much flexibility pathways should allow in care, pathways’ impact on public and private health insurance benefit design, what data is used to select pathway regimens and protocols, and ultimately what impact pathways may have on variation in care. The use and implementation of clinical treatment guidelines in practice was also explored from a variety of perspectives.
Cellular basis of graft versus host tolerance in chimeras prepared with total lymphoid irradiation.
Authors: M Gottlieb, S Strober, H S Kaplan
Journal: The Journal of Experimental Medicine (1980)

BALB/c mice given allogeneic (C57BL/Ka) bone marrow cells after toal lymphoid irradiation become stable chimeras approximately 80% donor-type and 20% host-type cells in the spleen. The chimeras doe not develop graft vs. host disease (GVHD). Purified cells of C57BL/Ka origin from the chimeras mediated GVHD in lightly irradiated C3H (third party), but not in BALB/c (host-strain) mice. Thus graft vs. host tolerance in the chimeras could not be explained by complete immunodeficiency of donor-type cells, serum blocking factors, or suppressor cells of host (BALB/c) origin. Clonal deletion or suppression of lymphocytes reactive with host tissues remain possible explanations. The transfer of donor-type chimeric spleen cells to BALB/c recipients given 500-550 rad whole-body irradiation WBI led to stable mixed chimerism in approximately 50% of recipients. The cells were presumably acting as tolerogens because similarly irradiated BALB/c mice given (BALB/c X C57BL/Ka)F1 spleen or bone marrow cells also became stable mixed chimeras.
Normal diet NaCl variation can affect the renal set-point for plasma pH-(HCO3-) maintenance.
Authors: M G Cogan, A V Carneiro, J Tatsuno, J Colman, R Krapf, R C Morris, A Sebastian
Journal: Journal of the American Society of Nephrology (1990)

In humans who are ingesting abundant NaCl, blood pH (pHb) and plasma bicarbonate concentration [HCO3-)p) change little or imperceptibly in response to the ingestion of alkali salts. We tested the hypothesis that such tight homeostatic regulation is an artifact of eating a culturally imposed NaCl-enriched diet, not a fundamental physiological trait of humans. In five normal men ingesting a constant acid-producing diet with a low intrinsic NaCl content (0.15 mEq/kg of body weight per day), we measured plasma and urine acid-base composition during four 7-day periods in which the diet was supplemented as follows: no supplements----NaHCO3 only----NaHCO3 plus NaCl----NaCl only. Each sodium supplement was 2.0 mmol/kg body weight per day. With no supplements, pHb was 7.43 +/- 0.005 and (HCO3-)p was 25.0 +/- 0.4 mEq/L. When NaHCO3 only was added, pHb rose 0.02 (to 7.45 +/- 0.004; P less than 0.01) and (HCO3-)p rose nearly 4 mEq/L (to 28.9 +/- 0.6 mEq/L, P less than 0.001). The rise in (HCO3-)p was sustained predominantly by an increased rate of renal bicarbonate reabsorption. When NaCl was added, (HCO3-)p returned to the earlier level, despite continued NaHCO3 supplementation (24.9 +/- 0.6 mEq/L), and remained there when NaHCO3 supplementation was subsequently stopped (24.1 +/- 0.5 mEq/L). Thus, tight homeostatic regulation of plasma acid-base composition in response to a change in dietary base occurred only when dietary NaCl was abundant. To our knowledge, this is the first study in normal humans that demonstrates that diet NaCl variations within the normal range significantly influence plasma acid-base composition.(ABSTRACT TRUNCATED AT 250 WORDS)
Overtube and over-the-wire, through-the-scope balloon-assisted ERCP in a patient with complex hypopharyngeal stenosis after neck surgery
Authors: Sandhya Mudumbi, Esraa Mohamed, Paul Kröner, Lucia Fry, Kondal Kyanam Kabir Baig, Klaus Mönkemüller
Journal: Endoscopy (2015)

A 64-year-old man with T2N0 squamous cell carcinoma of the tongue base underwent treatment with radiation, followed by glossolaryngectomy, bilateral neck dissection, and placement of an anterolateral thigh flap graft. After 1 year, he presented with acute cholangitis (abdominal pain, jaundice, fever, chills, and hypotension), making emergency endoscopic retrograde cholangiopancreatography (ERCP) mandatory. A computed tomographic scan of the neck showed hypopharyngeal stenosis and neck swelling as a result of the previous surgery ([Fig. 1 a], [Video 1]). At another institution, emergency ERCP had failed, and the patient was transferred to our institution for further treatment.
Retail Health Clinics: A Policy Position Paper From the American College of Physicians
Authors: Hilary Daniel, Shari Erickson
Journal: Annals of Internal Medicine (2015)

Retail health clinics are walk-in clinics located in retail stores or pharmacies that are typically staffed by nurse practitioners or physician assistants. When they entered the marketplace in the early 2000s, retail clinics offered a limited number of services for low-acuity conditions that were paid for out of pocket by the consumer. Over the past decade, business models for these clinics have evolved to accept public and private health insurance, and some are expanding their services to include diagnosis, treatment, and management of chronic conditions. Retail health clinics are one of several methods of health care delivery that challenge the traditional primary care delivery model. The positions and recommendations offered by the American College of Physicians in this paper are intended to establish a framework that underscores patient safety, communication, and collaboration among retail health clinics, physicians, and patients.
Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia
Authors: S Geyh, M Rodríguez-Paredes, P Jäger, C Khandanpour, R-P Cadeddu, J Gutekunst, C M Wilk, R Fenk, C Zilkens, D Hermsen, U Germing, G Kobbe, F Lyko, R Haas, T Schroeder
Journal: Leukemia (2015)
Regulation of MHC class II gene expression in macrophages by hematopoietic colony-stimulating factors (CSF). Induction by granulocyte/macrophage CSF and inhibition by CSF-1.
Authors: C L Willman, C C Stewart, V Miller, T L Yi, T B Tomasi
Journal: The Journal of Experimental Medicine (1989)

CSF-1 and granulocyte/monocyte CSF (GM-CSF) were shown to modulate the levels of Ia gene and protein expression in bone marrow-derived macrophages (BMM). Recombinant GM-CSF induced high levels of Ia expression, similar to the levels induced by INF-gamma, while IL-3 had no effect. In contrast, recombinant CSF-1 not only suppressed the basal levels of Ia gene and protein expression in BMM, but also inhibited the induction of Ia by IFN-gamma and GM-CSF. Basal levels of Ia were not inhibited by recombinant CSF-1 until after 16-24 h of culture, suggesting an indirect mechanism of suppression. IFN-alpha/beta and PGE2 were shown not to be involved in the CSF-1 inhibition of basal levels of Ia expression. However, the CSF-1-mediated suppression of both the basal levels of Ia expression and the induction of Ia in BMM by IFN-gamma and GM-CSF did correlate with the induction of cellular proliferation. These data imply that in addition to regulating hematopoiesis, CSFs may regulate the initiation of the immune response through their effects on Ia expression in macrophages.
The Effect of Small Artery Disease on the Occurrence and Management of Large Artery Disease
Authors: Louis R. Caplan
Journal: JAMA Neurology (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Surgical Management of Colorectal Cancer in the Laparoscopic Era: A Review of Prospective Randomized Trials
Authors: Mark Bloomston, Henry Kaufman, John Winston, Mark Arnold, Edward Martin
Journal: Journal of the National Comprehensive Cancer Network (2005)

The benefits of laparoscopy in benign diseases are quite clear. Patients generally can expect smaller incisions, less narcotic usage, quicker return of bowel function, and shorter hospitalizations. The benefits of laparoscopy in oncologic surgery are less clear, and laparoscopic oncology surgery has many critics. Early reports of long surgical times, high operating room costs, and alarming rates of port-site recurrences after laparoscopic colectomy for colorectal cancer all but stopped this less-invasive approach outside the confines of clinical protocols. As the results of larger retrospective studies began to refute these earlier detrimental claims, prospective randomized trials began to take a foothold. In this article, we review these randomized trials with particular attention to the perioperative effects of laparoscopic colectomy and the short-term oncologic outcomes.